EFFICACY AND SAFETY OF INTRAVENOUS DEXMEDETOMIDINE INFUSION FOR SEDATION IN COSMETIC DERMATOLOGY PROCEDURES: A SYSTEMATIC REVIEW
Main Article Content
Keywords
Dexmedetomidine, Conscious sedation, Cosmetic dermatology, Procedural sedation, Intravenous infusion, α₂-Adrenergic agonist, Cooperative sedation, Laser resurfacing, Hair transplantation, Chemical peel, Office-based cosmetic surgery, Respiratory safety, Hemodynamic stability, Patient satisfaction, Ramsay Sedation Scale (RSS), Richmond Agitation-Sedation Scale (RASS)
Abstract
Background: Cosmetic dermatology procedures, including extensive laser resurfacing, deep chemical peels, and hair transplantation, frequently necessitate effective conscious sedation. Traditional sedatives like midazolam and propofol carry risks of respiratory depression and paradoxical agitation. Dexmedetomidine, a highly selective α2-adrenergic agonist, provides "cooperative sedation" without respiratory depression, making it an attractive alternative.
Objective: This comprehensive review evaluates the clinical efficacy, safety profile, patient/surgeon satisfaction, and hemodynamic stability of intravenous (IV) dexmedetomidine infusion in cosmetic dermatology.
Methods: A systematic screening of randomized controlled trials (RCTs), prospective cohorts, and retrospective studies investigating dexmedetomidine sedation for dermatological subspecialties was conducted. Key endpoints extracted included sedation depth (Richmond Agitation-Sedation Scale [RASS] or Ramsay Sedation Scale [RSS]), respiratory metrics (oxygen saturation, respiratory rate), hemodynamic events (bradycardia, hypotension), and recovery timelines.
Results: Dexmedetomidine consistently achieves stable conscious sedation where patients remain easily arousable and cooperative during delicate procedures. The risk of respiratory depression is negligible compared to GABA-mimetic agents. However, its pharmacodynamic profile is marked by a predictable, dose-dependent decrease in heart rate and blood pressure, requiring careful titration. Onset and recovery times are longer than those of propofol, but are mitigated when combined with low-dose adjuncts. Both patient and surgeon satisfaction scores are high due to the lack of cognitive impairment and a clean field unhindered by airway devices.
Conclusion: Intravenous dexmedetomidine is a highly effective and safe sedative for cosmetic dermatology, offering a unique "cooperative" clinical state. While minor hemodynamic adjustments (bradycardia and hypotension) are common, they are manageable. Dexmedetomidine represents a robust procedural tool for office-based cosmetic surgery, provided appropriate cardiovascular monitoring is maintained.
References
2. Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. Anesthesiology. 1992;77(6):1134–1142.
3. Aho M, Erkola O, Kallio A, Scheinin H, Korttila K. Dexmedetomidine infusion for maintenance of anesthesia in patients undergoing abdominal hysterectomy. Anesth Analg. 1992;75(6):940–946.
4. Dyck JB, Maze M, Haack C, Vuorilehto L, Shafer SL. The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology. 1993;78(5):813–820.
5. Dyck JB, Maze M, Haack C, Azarnoff DL, Vuorilehto L, Shafer SL. Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology. 1993;78(5):821–828.
6. Khan ZP, Ferguson CN, Jones RM. Alpha2 and imidazoline receptor agonists: Their pharmacology and therapeutic role. Anaesthesia. 1999;54(2):146–165.
7. Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000;90(3):699–705.
8. Kamibayashi T, Maze M. Clinical uses of alpha2-adrenergic agonists. Anesthesiology. 2000;93(5):1345–1349.
9. Maze M, Scarfini C, Cavaliere F. New agents for sedation in the intensive care unit. Crit Care Clin. 2001;17(4):881–897.
10. Bekker AY, Kaufman B, Samir H, Doyle W. The use of dexmedetomidine infusion for awake craniotomy. Anesth Analg. 2001;92(5):1251–1253.
11. Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93(2):382–394.
12. Anttila M, Penttilä J, Helminen A, Vuorilehto L, Scheinin H. Bioavailability of dexmedetomidine after extravascular administration in healthy subjects. Br J Clin Pharmacol. 2003;56(6):691–693.
13. Mack PF, Perrine K, Kobylarz B, Schwartz TH, Lien CA. Dexmedetomidine and neurocognitive testing in awake craniotomy. J Neurosurg Anesthesiol. 2004;16(1):20–25.
14. Ebert TJ, Maze M. Dexmedetomidine: Another arrow for the clinician's quiver. Anesthesiology. 2004;101(3):568–570.
15. Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine: A review of clinical applications. Curr Opin Anaesthesiol. 2008;21(4):457–461.
16. Shukry M, Miller JA. Update on dexmedetomidine: Use in nonintubated patients requiring sedation for surgical procedures. Ther Clin Risk Manag. 2010;6:111–121.
17. Afonso J, Reis F. Dexmedetomidine: Current role in anesthesia and intensive care. Rev Bras Anestesiol. 2012;62(1):118–133.
18. Naaz S, Ozair E. Dexmedetomidine in current anaesthesia practice: A review. J Clin Diagn Res. 2014;8(10):GE01–GE04.
19. Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893–913.
20. Gerlach AT, Dasta JF. Dexmedetomidine: An updated review. Ann Pharmacother. 2007;41(2):245–252.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
